Cytochrome P450 2B6 is an enzyme that in humans is encoded by the CYP2B6gene. CYP2B6 is a member of the Cytochrome P450 group of enzymes. Along with CYP2A6, it is involved with metabolizing nicotine, along with many other substances.
This gene, CYP2B6, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to metabolize some xenobiotics, such as the anti-cancer drugs cyclophosphamide and ifosphamide.
Transcript variants for this gene have been described; however, it has not been resolved whether these transcripts are in fact produced by this gene or by a closely related pseudogene, CYP2B7. Both the gene and the pseudogene are located in the middle of a CYP2A pseudogene found in a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q.
^Guo Z, Raeissi S, White RB, Stevens JC (25 March 1997). "Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes.". Drug Metabolism and Disposition; The Biological Fate of Chemicals25 (3): 390–393. PMID9172960.
Ngaimisi E, Mugusi S, Minzi OM, et al. (2010). "Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients". Clin. Pharmacol. Ther.88 (5): 676–84. doi:10.1038/clpt.2010.172. PMID20881953.
Smith G, Stubbins MJ, Harries LW, Wolf CR (1998). "Molecular genetics of the human cytochrome P450 monooxygenase superfamily". Xenobiotica28 (12): 1129–65. doi:10.1080/004982598238868. PMID9890157.
SvÃ¤rd J, Spiers JP, Mulcahy F, Hennessy M (2010). "Nuclear Receptor-Mediated Induction of CYP450 by Antiretrovirals: Functional Consequences of NR1I2 (PXR) Polymorphisms and Differential Prevalence in Whites and Sub-Saharan Africans". J. Acquir. Immune Defic. Syndr.55 (5): HASH(0x271b490). doi:10.1097/QAI.0b013e3181f52f0c. PMID20861742.
Melanson SE, Stevenson K, Kim H, et al. (2010). "Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation". Am. J. Hematol.85 (12): 967–71. doi:10.1002/ajh.21889. PMID21108329.
Nelson DR, Zeldin DC, Hoffman SM, et al. (2004). "Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants". Pharmacogenetics14 (1): 1–18. doi:10.1097/00008571-200401000-00001. PMID15128046.
Figueroa SC, de Gatta MF, GarcÃa LH, et al. (2010). "The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy". Ther Drug Monit32 (5): 579–85. doi:10.1097/FTD.0b013e3181f0634c. PMID20720517.
Shimada M, Miyagawa T, Kawashima M, et al. (2010). "An approach based on a genome-wide association study reveals candidate loci for narcolepsy". Hum. Genet.128 (4): 433–41. doi:10.1007/s00439-010-0862-z. PMID20677014.
Jamshidi Y, Moreton M, McKeown DA, et al. (2010). "Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection". J. Antimicrob. Chemother.65 (12): 2614–9. doi:10.1093/jac/dkq369. PMID20952418.
Lindfelt T, O'Brien J, Song JC, et al. (2010). "Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms". Ann Pharmacother44 (10): 1572–8. doi:10.1345/aph.1P141. PMID20841522.
Chung JY, Cho JY, Lim HS, et al. (2011). "Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin". Drug Metab. Dispos.39 (1): 92–7. doi:10.1124/dmd.110.035246. PMID20876786.